1. Ouchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrabe type I matriz metalloproteinase digest interstitial collagens and other extacellular matriz macromolecules. J Biol Chem 1997; 272: 2446-2451. 2. Freije JM, Díez.Itza I, Balbín M, Sánchez LM, Blasco R, Tolicia J et al. Molecular cloning and expression of collagenase-3, anovel human matriz metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766-16773. 3. Mitchell Pg, Magna Ha, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ et al. Cloning, expression and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthriticcartilage. J Clin Investg 1996; 97: 761-768. 4. Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A et al. Matrix metalloproteinase 13 (collagenase-3) in human rheumatoid synovium. Arthritis Rheum 1997; 40: 1391-1399. 5. Knäuper V, Cowell S, Smith B, López-Otín C, O´Shea M, Morris H et al. the role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3. J Biol Chem 1997; 40: 7608-7616. 6. Ashworth JL, Murphy G, Rock MJ, Sherratt MJ, Shapiro SD, Shuttleworth CA et al. Fibrillin degradation by matriz metalloproteinases: implications for connective tissue remodelling. Biochem J 1999; 340: 171.181. 7. Uría JA, Balbín M, López JM, Alvarez J, Vizoso F, Takigawa M et al. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol 1998; 153: 91-101. 8. Johanson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kahari VM. Expression of collagenase-3 (MMP-13) in squamous cell carcinomas of the head and neck. Am J Pathol; 151: 499-508. 9. Cazorla M, hernández L, Nadal A, Balbín M, López Jm, Vizoso F et al. Collagenase-3 expression is asocciated with advanced local invasión in human squamous cell carcinomas of the larynx. J Pathol 1998; 186: 144-150. 10. Airola K, Johansson N, Kariniemi AL, Kahari VM, Saarialho-Kere UK. Huma collagenase-3 is expressed en malignat squamous epithelium of the skin. J Investg Dermatol 1997; 109: 225-232. 11. Airola K, Karonen T, Vaalamo M, Lohi J, Kariniemi AL, Keski-Oja J et al. Expression of collagenases-1 and-3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80:733-743. 12. Johansson N, Vaalamo M, Grenman S, Hietanen S, Klemi P, Saarialho-Kere U et al. Collagenase-3 (MMP-13) is expressed by tumors cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999; 154: 469-480. 13. Bostrom PJ, Ravanti L, Reunanen N, Aaltonen V, Soderstrom KO, Kahari Vm et al. Expression of collagenase-3 (MMP-13) in transitional cell carcinoma of the urinary bladder. Int J Cancer 2000; 88:417-423. 14. Etoh T, Inoue H, Yoshikawa Y, Barnard GF, Kitano S, Mori M. Increased expression of collaganase-3 (MMP-13) and MT1-MMP in esophageal cancer is related to cancer aggressiveness. Gut 2000; 47: 50-56. 15. UICC. TNM classification of malignant tumors. Berlin Springer Verlag 1987; 4thed. 16. Vaitukaitis JL. Production of antisera with small doses of imnunogen multiple intradermal injections. Methods Enzymol 1981; 73: 46-52. 17. Grigioni WF, D´Errico A, Fortunato C, Florentico M, Manzini AM, Stetler-Stevenson WG et al. Prognosis of gastric carcinoma revealed by interactions between tumors cells and basement membrane. Mod Pathol 1994; 7:220-225. 18. Nuovo GJ, McConell PB, Simsir A, Valea F, French DL. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complemetary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55: 267-275. 19. Seir CMF, Kubben FJGM, Ganesh S et al. Tisuue levels of matriz metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413-417. 20. Allgayer H, Babic R, Beyer BCM. Grútzner KU, Tarabichi A, Schildberg FW. Prognosis revelance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncol 1998; 55: 152-160. 21. Honda M, Mori M, Ueo H, Sugimachi K, akiyoshi T. Matriz matalloproteinase-7 expression in gastric carcinoma. GUT 1996; 39: 444-448. 22. Senota A, Itoh F, Yamamoto H, Adachi Y, Hinoda Y, Imai K. Relation of matrilysin messenger RNA expresión with invasive activity in human gastric cancer. Clin Exp Metastasis 1998; 16: 313-321. 23. Nomura H, Sato H, Seiki M, Mai M, Okada Y. expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263-3266. 24. Knáuper V, Will H, López-Otín; Smith B, Atkinson SJ et al. cellular mechanism for human procollagenase-3 (MMP-13) activation: Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem !))&; 271: 17124-17131. 25. Cowell S, Knäuper V, stewart ML, D´Ortho MP, Stanton H, Hembry RM et al. Induction of matriz metalloproteinase activation cascades based ion membrane-type-1 matriz metalloproteinase. Biochem J 1998; 331: 453-458. 26. Chambers AF, Matrisian LM. Changing views of the role of matriz metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270. 27. Uría JA, Stanhle-Bäckdahl M, Seiki M, Fueyo A, López- Otín C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 1997; 57:4882-2888. 28. Nielsen BS, Rank F, López JM, Balbín M, Vizoso F, Lund LR et al. Collagenase-3 expression in breast myofibroblasts as a marker of transition of ductal carcinoma in situ lesions to invasive ductal. Cancer Res 2001; 61: 7091-7100. 29. Vizoso Fj, Martínez A, Vázquez J, Lamelas ML, Rodil A, García Muñiz JL. Significación biológica y clínica de las enzimas proteolíticas y sus inhibidores en los carcinomas humanos. Cir Esp 2000; 68: 471-485. 30. Gómez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological finctions. Eur J Cell Biol 1997; 74: 111-122. 31. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FK. A synthetic metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1994; 54: 2087-2091. 32. Drummond AH, Beckett P, Bone EA, Brown PD, Davis M, Golloway WA et al. BB-2516: an orally bioavailable matriz metalloproteinase inhibitor with efficacy in animal caner models. Proc Am Assoc Cancer Res 1995; 36: 100. 33. Nemunaitis J, Poole C, Primrose J et al. Cobined analusis of studies of the effects of the matriz metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for long-term studies. Clin Cancer res 1998; 4: 1101-1111. 34. Tierney GM, Griffin NR, Stuart RC, Kasem H, Lynch KP, Lury JT et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999; 35: 563-568.
|